Phase 2 Completed N=98 Prevention

COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients

Source: ClinicalTrials.gov NCT04364802 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Dec 2022

Primary outcomePrimary: Percent of Healthcare Workers Testing Positive for COVID-19. — 0; 0 percentage of healthcare workers

Summary

Povidone-iodine (PVP-I) is a broad-spectrum antiseptic with activity against bacteria, fungi, and viruses. It has been previously used in both intranasal preparations against Methicillin Resistant Staphylococcus Aureus (MRSA) as well as oral preparations in in-vitro studies of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), influenza H1N1, and rotavirus with good efficacy. This study will evaluate the efficacy of PVP-I as prophylaxis in Coronavirus Disease 2019 (COVID19)-negative front-line health care workers, hospital patients, and community members.

Outcome Measures

Outcome	Result	p-value
PRIMARY Percent of Healthcare Workers Testing Positive for COVID-19.	0; 0	—
PRIMARY Percent of Patients Testing Positive for COVID-9.	0; 0	—
PRIMARY Percent of Community Participants Testing Positive for COVID-9.	0; 0	—
SECONDARY PVP-I Ease of Use	4.48; 4.43; 4.77	—
SECONDARY PVP-I Comfort	3.25; 4.00; 3.00	—

Eligibility Criteria

Inclusion Criteria

healthcare worker OR
patient with expected hospital stay of 7+ days OR
patient admitted for major surgery OR
community member
COVID19 negative by nasal swab test
asymptomatic for COVID19
able to consent

Exclusion Criteria

positive for COVID19 by nasal swab
symptomatic for COVID19
unable to consent

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04364802). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.